RADICAVA® (edaravone) Video Library

Learn more about RADICAVA® for the treatment of ALS through a series of educational videos.

ALS specialist testimonials

Neurologists who specialize in the treatment of ALS share their thoughts on RADICAVA® and discuss their experience prescribing treatment.

Considerations When Prescribing

Ghazala Hayat, MD, FAAN, explains why she recommends RADICAVA® for all of her patients who are newly diagnosed with ALS and why the inclusion criteria from the pivotal trial doesn’t affect her decision to prescribe treatment.

Considerations When Prescribing

Incorporating RADICAVA® Into Your Treatment Considerations

Safety and Personal Experience When Prescribing

ALS experts present on RADICAVA®

A panel of ALS experts discuss the benefits, risks, and appropriate uses of RADICAVA®.

Clinical Pharmacology

Learn about the pharmacokinetics, dosing, and administration of RADICAVA®.

Clinical Pharmacology

Pivotal Trial in ALS

ALS Functional Rating Scale–Revised

Efficacy and Safety

How to infuse RADICAVA®

Watch a brief video that explains how to administer and store RADICAVA®. See full Prescribing Information for complete dosing and administration information.

Important Safety Information

Hypersensitivity Reactions

Radicava® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients in Radicava®. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported. Patients should be monitored carefully for hypersensitivity reactions, and if they occur, discontinue Radicava®, treat per standard of care, and monitor until the condition resolves.

Sulfite Allergic Reactions

Radicava® contains sodium bisulfite, and may cause allergic type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown, but occurs more frequently in asthmatic people.

Most Common Adverse Reactions

Most common adverse reactions (at least 10% and greater than placebo) are contusion, gait disturbance, and headache.


Based on animal data, Radicava® may cause fetal harm.

Geriatric Use

No overall differences in safety or effectiveness were observed between patients 65 years of age and older and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Radicava® is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Please see full Prescribing Information.

For more information about RADICAVA®, call 1-888-292-0058.